Poseida Therapeutics, Inc. (PSTX) Tops Q3 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts PSTX Hot Sheet
Price: $9.50 --0%
Financial Fact:
Preferred dividends: -142.41K
Today's EPS Names:
OMID, SICP, SCKT, More
Financial Fact:
Preferred dividends: -142.41K
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q3 EPS of $0.21, $0.63 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $71.75 million versus the consensus estimate of $16.25 million.
For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
- OmniPhi Secures Strategic Investment from Beeks Group and Launches Beeks Sovereign AI for Capital Markets
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
